Collaboration and License Option Agreement Sample Contracts

Collaboration and License Option Agreement Between ADARx Pharmaceuticals, Inc. and The Puerto Rico Branch of AbbVie Biotechnology Ltd Dated as of May 9, 2025
Collaboration and License Option Agreement • September 4th, 2026 • ADARx Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This Collaboration and License Option Agreement (this “Agreement”) is made and entered into as of May 9, 2025 (the “Effective Date”) by and between ADARx Pharmaceuticals, Inc., a Delaware corporation (“ADARx”), and the Puerto Rico branch of AbbVie Biotechnology Ltd, a Bermuda corporation (“AbbVie”). ADARx and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

View SourceView Similar (2)
Contract
Collaboration and License Option Agreement • September 8th, 2020

Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

View Source
AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement
Collaboration and License Option Agreement • January 24th, 2024

• A new public-private collaboration aims to discover new active agents for treatment and prophylaxis of infections of immunocompromised patients.

View Source
Portions of this exhibit marked [*] are requested to be treated confidentially. COLLABORATION AND LICENSE OPTION AGREEMENT
Collaboration and License Option Agreement • April 8th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • Indiana

This Collaboration and License Option Agreement (“Agreement”) is effective as of February 10, 2009 (“Effective Date”). The parties to this Agreement are Eli Lilly and Company having its principal offices at Lilly Corporate Center, Indianapolis, IN 46285 (“Lilly”), and Magen BioSciences, Inc., having its principal offices at 100 Beaver St., Suite 101, Waltham, MA 02453 (“Magen”). Lilly and Magen may be referred to herein individually as a “Party”, and collectively as the “Parties”.

View Source